Navigation Links
TGen-led research shows ability to do next-generation sequencing for patients with advanced cancers
Date:10/30/2013

SCOTTSDALE, Ariz. Oct. 30, 2013 A pilot study led by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare shows that, even for patients with advanced and rapidly transforming cancer, researchers can find potential therapeutic targets using the latest advances in genomic sequencing.

Sequencing spells out, or decodes, the billions of letters of DNA and other genomic data so that clinicians can discover what genetic changes might lead to cancer.

Better optics and faster computers, which are the hallmarks of today's Next Generation Sequencing (NGS), are leading to genomic analysis that enables development of new drugs that target specific genetic mutations. However, because patients' tumors often contain multiple abnormalities, their cancer often progresses beyond initial targeted therapies.

Researches showed that the most cutting-edge NGS whole genome sequencing (WGS), and even more advanced whole transcriptome sequencing (WTS) can reveal larger numbers of targets in an individual's tumor, and that these "could be addressed using specific therapeutic agents, and perhaps reduce the chance of progression," according to the pilot study published today in the scientific journal PLOS ONE.

The study A Pilot Study Using Next Generation Sequencing in Advanced Cancers: Feasibility and Challenges reported results on nine patients evaluated at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership of Scottsdale Healthcare and TGen.

"Patients with advanced cancer often exhaust treatment options. Targeting a single abnormality is not sufficient to prevent progression," said Dr. Glen Weiss, an Associate Professor in TGen's Cancer and Cell Biology Division and the study's lead author.

"We demonstrate the feasibility of using NGS in advanced cancer patients so that treatments for patients with progressing tumors
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. TGen-led study discovers dramatic changes in bacteria following male circumcision
2. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
3. Research reveals first evidence of hunting by prehistoric Ohioans
4. Diabetes Research Institute develops oxygen-generating biomaterial
5. APS issues new policy requiring identification of sex or gender in reporting scientific research
6. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
7. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
8. U of Alberta researcher steps closer to understand autoimmune diseases
9. Research on flavanols and procyanidins provides new insights into how these phytonutrients may positively impact human health
10. A project to research biological and chemical aspects of microalgae to fuel approach
11. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... increasingly turning to a slow-release form of a powerful painkiller ... warn. The trend is raising alarm as the number of ... opioid 100 times more potent than morphine, rises. , Addicts ... of fentanyl through the skin into the bloodstream over the ...
... on a promising new vaccine against a pre-cancerous cervical ... non-invasive cervical cancer, according to a study presented today ... Frontiers in Cancer Prevention Research meeting in Baltimore. ... originally published in early October, confirmed the vaccine's efficacy ...
... will provide valuable information for assessing environmental hazards caused ... Sciences (NIEHS), one of the National Institutes of Health, ... to public health and safety workers on contaminants in ... demographic information for local populations. , The ...
Cached Biology News:Prescription pain patch abuse blamed for increase in deaths 2Prescription pain patch abuse blamed for increase in deaths 3Updated data on novel HPV vaccine confirms efficacy in large population 2FDA approves child-friendly AIDS medicine 2
(Date:12/17/2014)... 17, 2014 Based on the ... surgical imaging market is dominated by four major ... imaging market. These players include GE Healthcare (U.K.), ... (Germany). , Full Report Copy at ... Healthcare can be attributed to its strong product ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... December 17, 2014 Xeno Diagnostics ... following its most recent COLA inspection. Xeno has ... a national healthcare accreditation organization. Accreditation is earned ... quality in day-to-day operations, demonstrate continued accuracy in ... rigorous on-site laboratory survey. , While ...
(Date:12/17/2014)... Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... disease, today announced the next step in its expanded ... solutions provider with the naming of current Chief Operating ... Executive Officer, while current Chairman of the Board and ... as Chairman. These changes are effective January 1, 2015. ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... start-up, CEOs, business development executives, and service providers from ... ... the globe, MASSAPEQUA, N.Y. and CLEVELAND, April 11 ... Corporation, the Cleveland-based bioscience business,formation, recruitment, and acceleration initiative, are ...
... DIEGO, California, April 11 , - Newly ... -, Ortho Biotech Oncology Research & Development ... & Development, L.L.C., will announce,results from studies of ... the American Association for Cancer Research (AACR),2008 Annual ...
... Biopure,Corporation (Nasdaq: BPUR ) announced today ... Regulatory Agency (MHRA) has found the,company,s Pennsylvania ... the principles and guidelines of good manufacturing ... company received confirmation,that it has responded successfully ...
Cached Biology Technology:IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference 2IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference 3Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets 2Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets 3Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets 4Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets 5Biopure Operations Compliant With U.K. Manufacturing Guidelines 2Biopure Operations Compliant With U.K. Manufacturing Guidelines 3
...
Sterile detoxified 10% bovine serum albumin (BSA) in Iscoves MDM. This BSA has been selected to support the optimal colony growth of human hematopoietic progenitor cells in methylcellulose-based medi...
... A full-featured high-performance ICP-MS system designed for ... interface, Omega II off-axis ion lens, true ... 7500a can handle the widest range of ... the 7500a now includes as standard Agilents ...
... to the DH-2000, except that it uses a ... wavelength range and comes with a shutter (controlled ... 5 Hz) The DH-2000 Deuterium Tungsten ... deuterium and tungsten halogen light sources in a ...
Biology Products: